Lewy bodies are found in Parkinson disease and related disorders and are extensively phosphorylated at Ser-129 (S129), but whether S129 phosphorylation mediates >-synuclein aggregation and neurotoxicity has been controversial. We used recombinant adenoassociated virus to overexpress >-synuclein in the rat nigrostriatal system. Rats were injected with recombinant adeno-associated virus 2/8 expressing either human wild-type (wt) or mutant >-synuclein with S129 replaced by alanine (S129A) or aspartate (S129D). Contralateral substantia nigra injections containing empty vector served as controls. Both wt and S129 mutants resulted in significant dopaminergic cell loss in the recipients by 6 weeks, but there were only small decreases in nigrostriatal terminal density and tyrosine hydroxylase expression. There were no significant differences in dopaminergic cell loss, nigrostriatal terminal density, or tyrosine hydroxylase expression among the wt and S129 mutants. Furthermore, we did not observe any differences in >-synuclein aggregate formation or distribution among wt and either S129 mutant. These findings contrast with those from previous studies and suggest that injections of both S129 phosphorylation mutants result in dopaminergic neurotoxicity similar to wt injections. Further study is needed to clarify the effects of these S129 mutants and >-synuclein phosphorylation in mammalian systems.
INTRODUCTION
Parkinson disease (PD) is the most common neurodegenerative movement disorder and affects about 1% of the population older than 65 years. The pathological hallmarks of PD are progressive loss of nigrostriatal dopamine neurons, swollen dystrophic neurites, and characteristic filamentous intracellular inclusions called Lewy bodies. These inclusions are not unique to PD because they are also found in related disorders such as dementia with Lewy bodies and multiple system atrophy (1Y3). A principal component of Lewy bodies is >-synuclein, a soluble 140-amino acid protein that is abundantly expressed in the brain and is enriched in synaptic terminals (4) . Although its normal function remains unclear, several point mutations in the >-synuclein gene (PARK1/SNCA) have been identified and linked to families with autosomal dominant parkinsonism (5Y7). Gene duplication and triplication have also been linked to familial parkinsonism, and a gene-dosage effect correlates with earlier disease onset and symptom severity (8Y10). The fact that Lewy bodies are also found in these familial forms of parkinsonism further supports a role for >-synuclein in PD pathogenesis (11) .
Abnormal folding, aggregation, and deposition of >-synuclein may be key steps in the pathogenesis of sporadic and familial PD (12) . >-Synuclein self-aggregates and fibrillizes in vitro, forming aggregates suggestive of those seen in Lewy bodies and Lewy neurites (13, 14) . Moreover, missense mutations in >-synuclein also result in accelerated fibril formation (15, 16) and oligomerization (17) . Dose increases (i.e. duplication and triplication) of the >-synuclein gene promote this aggregation and deposition in insoluble fractions, consistent with inclusion formation (18) . Animal models of human >-synuclein overexpression likewise demonstrate increased aggregates and neurotoxicity and recapitulate features of PD (19Y21) .
Epigenetic factors such as phosphorylation also influence >-synuclein fibrillization and aggregate formation. For example, the C-terminal portion of >-synuclein contains several phosphorylation sites (22, 23) , and there is evidence that Ser-129 (S129) phosphorylation accelerates >-synuclein fibrillization and enhances neurotoxicity. Ser-129 is extensively phosphorylated in brains from patients with both sporadic and familial PD (24, 25) , as well as dementia with Lewy bodies (26) . Although a small proportion (G5%) of >-synuclein is normally phosphorylated, nearly 90% of >-synuclein in Lewy bodies is phosphorylated at S129. Furthermore, in vitro S129 phosphorylation enhances fibril formation (24) . In transgenic flies expressing human >-synuclein with mutation of S129 to either alanine (S129A) to prevent phosphorylation or aspartate (S129D) to mimic phosphorylation, blocking S129 phosphorylation suppresses dopamine neuronal loss, whereas S129D enhances >-synuclein neurotoxicity (27) . In addition, overexpression of the Drosophila G-proteinY coupled receptor kinase 2 (GRK-2), which selectively phosphorylates >-synuclein at S129, results in enhanced neurotoxicity. Blockade of S129 phosphorylation (S129A) also increases inclusion formation and correlates with decreased >-synuclein neurotoxicity, suggesting that aggregates may be neuroprotective and sequester potentially toxic >-synuclein species. However, a recent study in rats found the opposite and demonstrated that the S129A mutant was more toxic than wild-type (wt) human >-synuclein and associated with decreased intracellular aggregates, whereas the phosphomimic S129D seemed to be neuroprotective (28) . Thus, whether phosphorylation at S129 plays a critical role in mediating >-synucleinYinduced dopaminergic neurotoxicity remains uncertain.
In this study, we examine the effect of >-synuclein S129 phosphorylation state on dopaminergic neurotoxicity in a rat model of PD. Previous studies have established that viral vectorYbased overexpression (using either recombinant adenoassociated virus [rAAV] or lentivirus) of human >-synuclein in the rat nigrostriatal system results in progressive dopaminergic cell loss, synuclein-rich aggregates, and dystrophic neurites (29, 30) . New rAAV serotypes are increasingly being used, and they show greater transduction efficiency and delivery of transgene into the nervous system compared with the commonly used rAAV2/2 (31Y33). Here, we present new data using rAAV2/8 for delivery of >-synuclein S129 phosphorylation mutants; we find no significant differences in nigrostriatal dopaminergic toxicity or morphology of >-synuclein aggregates among wt and S129A/D mutants.
MATERIALS AND METHODS

Virus Production
Construction of rAAV vectors used to express human wt >-synuclein was as previously described (34) . Overlap extension polymerase chain reaction was used to generate >-synuclein S129 mutants (S129A and S129D) using the mammalian pcDNA-synuclein (human wt, GenBank L08850) vector as template and previously designed primers (available by request). The S129 mutant and wt >-synuclein were then cloned into AAV-CBA-WPRE vector using the subclone internal ribosomal entry siteYenhanced green fluorescence protein (pIRES2-EGFP) (Clontech, Mountain View, CA). We also constructed an empty vector, AAV-CBA-WPRE, with no transgene (kindly provided by Dr Miguel Sena-Esteves, Massachusetts General Hospital, Boston, MA). Recombinant AAV2/8 virus was generated via tripartite transfection of the cis-transgene, packaging (rep and cap) genes, and helper plasmid into HEK 293A cells (Harvard Gene Therapy Initiative, Harvard Medical School). Viral particles were purified by iodixanol density gradient, isolated, and titered by dot blot hybridization. Final titers for virus were for >-synuclein wt 1.4 Â 10 13 gc/mL, S129D 1.4 Â 10 13 gc/mL, S129A 7.7 Â 10 12 gc/mL, and empty vector 1.16 Â 10 14 gc/mL.
Stereotaxic Viral Injections
All animal protocols and procedures were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care. The nigrostriatal system is essentially unilateral, thus each animal received bilateral stereotaxic injections of rAAV into the substantia nigra (SN). In most animals, virus with empty vector was injected contralateral to virus encoding human wt or mutant S129A/D >-synuclein. Sprague-Dawley rats (300Y350 g) were anesthetized and placed in a Kopf stereotax, and bilateral small skull holes were drilled to expose the dura over the injection sites. Coordinates for SN injections from bregma were anteriorposterior (AP) j5.2, medial-lateral (ML) T2.0, and dorsalventral (DV) j7.4 from the dural surface and targeted the central SN pars compacta (SNc). For each virus, 1.4 Â 10 10 gc in 2 KL were injected at 0.2 KL per minute using a microinjection pump (Stoelting Co, Wood Dale, IL) with a 10-KL Hamilton syringe and a 33-gauge needle. After injection, the syringe remained in situ for 5 minutes before withdrawal.
Tissue Preparation and Immunohistochemistry
At 2 or 6 weeks postinjection, rats were deeply anesthetized and transcardially perfused with cold 0.1 M PBS (pH 7.4) followed by 4% paraformaldehyde in PBS.
Brains from a subset of 6-week-old animals were removed without fixation, and the striatum and midbrain were quickly dissected on ice and snap-frozen in isopentane for use in dopamine content measurement and immunoblotting. Perfused brains were postfixed for 24 hours, then cryoprotected in 30% sucrose/PBS, and serially sectioned at 40 Hm on a sliding microtome into 12 wells (forebrain and midbrain were separately blocked). Sections were collected and stored in cryoprotectant, 30% sucrose and 30% ethylene glycol in PBS, until processed and analyzed. Briefly, free-floating sections were rinsed with PBS, then treated for 3 to 5 minutes with 10% methanol and 3% H 2 O 2 to inhibit endogenous peroxidases, permeabilized with 0.3% Triton X-100 in PBS, and blocked in 5% normal goat serum. Coronal sections through the striatum and nigra were immunostained with primary antibodies to tyrosine hydroxylase ([TH] 1:10,000 dilution; Millipore, Billerica, MA) or >-synuclein LB509 (1:1000 dilution; Zymed Laboratories, Inc, San Francisco, CA) overnight at 4-C. After washing, immunostaining was visualized with either fluorescent secondary (1:200 dilution; Alexa Fluor 488, Molecular Probes, Eugene, OR; or Cy3, Jackson ImmunoResearch, West Grove, PA) or biotinylated secondary, followed by avidin-biotin (Vectastain Elite Kit, Vector Labs, Burlingame, CA), and 3,3 ¶-diaminobenzidine reaction. Immunostained sections were washed, mounted on Superfrost slides, and coverslipped (GVA mount, Zymed Laboratories, Inc, San Francisco, CA; or Permount, Sigma Chemicals, St Louis, MO). In some animals, adjacent coronal sections were also Nissl stained with 0.05% cresyl violet per standard protocols.
Microscopy and Stereology
Immunostained sections were viewed using an Olympus BX51 microscope with bright-field and epifluorescence attachment. Photomicrographs were taken with an Olympus DP70 digital camera and adjusted only for suitable contrast and brightness. To maintain detail, wide-field images were photo-montaged from high-power photos using Adobe Photoshop CS3. Double label immunofluorescence images of cells were obtained using a Zeiss LSM510 confocal microscope system. Images were obtained with multitracking to minimize spectral overlap.
Nigrostriatal cell loss was assessed by counting THimmunoreactive cells in the SNc, including the adjacent pars lateralis and caudal dense cell group ventral to the medial lemniscus and retrorubral area, using unbiased stereology according to the optical fractionator principle (35) . At least 8 sections (each 240 Km apart) through the SN for each animal were analyzed and counted using the Olympus CAST Stereology System. Sampling intensity was sufficient for a coefficient of error for the counting protocol of less than 0.1.
Striatal TH Terminal Expression
Semiquantitative analysis of TH expression in nigrostriatal terminals at 6 weeks postinjection virus was performed by measurement of optical density of immunofluorescence intensity scans using a Scan Array Express (Perkin Elmer, Boston, MA). All sections for analysis were handled, washed, and immunostained at the same time using common reagents to minimize interanimal variability. Striatal sections approximately 1 mm rostral to the decussation of the anterior commissure were immunostained with antibody to TH and fluorescent secondary-Cy3 (Molecular Probes) and scanned using 543-laser excitation. Using ImageJ (National Institutes of Health), mean gray value of fluorescence intensity within the dorsolateral striatum was obtained for each section and normalized to background, corpus callosum.
Immunoblotting
Striatal and midbrain tissues were separately suspended in 300 KL of lysis buffer (50 mM Tris-HCl, pH 7.4; 175 mM NaCl; 5M EDTA, pH 8.0; and protease inhibitor [Roche]) and homogenized on ice for 10 to 15 seconds. Each sample was centrifuged for 15 minutes at 4-C, filtered, and then 1% Triton X-100 added to the lysate. After 1 hour of incubation on ice, lysates were centrifuged for 60 minutes at 4-C to collect the triton-XYinsoluble fraction. Triton-soluble lysate was separated, and the insoluble pellet was resuspended in 2% sodium dodecyl sulfateYcontaining lysis buffer (Tritoninsoluble fraction), then sonicated for 10 seconds. Protein concentration for each lysate was determined by bicinchoninic acid assay. Five micrograms of each sample were separated on 10% to 20% Tris-glycine precast gel (Invitrogen, San Diego, CA), transferred to polyvinylidene diflouride, and immunoblotted for TH (mouse TH-2 antibody, Sigma) or >-synuclein (mouse Syn1, BD Transduction Laboratories, or Syn [LB509], Zymed, antibody). All blots were immunostained for glyceraldehyde-3-phosphate dehydrogenase (rabbit antibody, Abcam, Cambridge, MA) as loading control. In some cases, samples for each condition were pooled. Immunoblotted >-synuclein, TH, and glyceraldehyde-3-phosphate dehydrogenase were detected with secondary antibody conjugated to horseradish peroxidase and reacted with enhanced chemiluminescence (GE Healthcare, Waukesha, WI) as per protocol. Films were scanned using a FluorChem system and analyzed with ImageJ software (National Institutes of Health). Tyrosine hydroxylase and >-synuclein contents for each sample were normalized to glyceraldehyde-3-phosphate dehydrogenase.
Dopamine Content
Striatal tissue was thawed, homogenized, and mixed in lysis buffer with dihydrobenzylamine added as internal control. Dopamine and 3,4-dihydroxyphenlyacetic acid were measured by high-performance liquid chromatography with electrochemical detection and normalized to protein content per sample (36) .
Statistics
All data were expressed as group mean T SEM. Stereological estimates of nigral TH cell survival, mean striatal terminal density, and dopamine measurements were analyzed using 1-way analysis of variance with Bonferonni multiple comparison post hoc (Prism GraphPad 4.03, San Diego, CA) unless otherwise stated.
RESULTS
We used the pseudotyped rAAV2/8 for delivery of transgene because recent rAAV serotype comparisons have shown increased transduction efficiency over that of rAAV2/2 (33, 36) . Transgene expression for rAAV2/8 is also markedly enhanced over rAAV2/2 and rapidly reaches a steady state by 2 to 4 weeks (37, 38) . Rat SN were stereotaxically injected with equal volume and genome copies of rAAV vector encoding either human wt or S129 phosphorylation mutant (S129A for substitution to alanine or S129D for aspartate) >-synuclein, followed by an internal ribosomal entry site and the reporter gene EGFP, resulting in bicistronic expression. To control for possible viral toxicity and injection effects, the contralateral SN of several rats was injected with empty rAAV vector and used as an internal control. Based on preliminary experiments with rAAV2/8, its rapid transgene expression and spread, we selected 2-and 6-week time points postinjection for analysis of wt and S129A/D >-synuclein toxicity in the nigrostriatal system. FIGURE 2. The distribution of nigrostriatal terminals immunostained for tyrosine hydroxylase (TH) and human >-synuclein (LB509) at 6 weeks postinjection. Columns 1 and 2 compare striatal TH terminal labeling after empty vector control (A, D, G) and >-synuclein (B, E, H) injection in the same animal. There is striatal TH terminal loss in the dorsal striatum on the side of >-synuclein injection that seems more prominent for both S129 mutants (E, H) than for the wt (B). The distribution of >-synucleinYpositive (LB509 antibody) striatal terminals (C, F, I) is similar among wild-type (wt) and mutant recipient animals. Insets reveal high-power detail of >-synucleinYpositive nigrostriatal terminals. Bars indicate respective magnification (Km).
The patterns of transgene expression for all rAAV were similar. For >-synuclein viruses, EGFP expression marked cells transduced with rAAV in the SN. All cells with EGFP coexpressed >-synuclein as assessed by double immunofluorescence. rAAV2/8 was neurotrophic; we did not observe transduction of glial elements. At 2 and 6 weeks postinjection, EGFP expression was widespread for >-synuclein rAAV and included cells not only in the SNc, but also in the adjacent pars reticulata (SNr), ventral tegmental nucleus, and a portion of the ventral mesencephalic reticular formation (Fig. 1) . These findings are consistent with the reported enhanced transduction efficiency of rAAV2/8 compared with rAAV2/2 in the SN (33, 34, 37) .
In addition to cellular expression of >-synuclein within the SN, immunostaining for human >-synuclein using the LB509 antibody (specific for amino acid residues 115Y122) also demonstrated extensive transport of >-synuclein to nigrostriatal terminals (Fig. 2) . Animals without extensive nigrostriatal labeling suggested failed or misplaced injections and were excluded from the analysis. Synuclein-positive terminals were widespread and found throughout the dorsal striatum (caudatoputamen), extending rostrally to the striatal pole and several millimeters caudal to the anterior commissure. These findings are consistent with the topographic distribution of nigrostriatal projections (39) and confirm Protein from left and right midbrain samples was probed with primary antibody to >-synuclein and TH, followed by secondary horseradish peroxidaseYconjugated antibody and enhanced chemiluminescence detection. Bands were quantified and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) loading control. The ratio of >-synuclein and TH for the >-synuclein (ipsilateral) versus empty vector (contralateral) side was calculated for each animal. Blots show >-synuclein overexpression for most animals, but there was variable expression as shown for the 2 wt samples. Decreased TH expression is also shown for wt and S129 mutants. transduction of a large proportion of SNc neurons for each case. Double labeling of SN with antibodies to >-synuclein (or GFP) and TH also demonstrated that rAAV injections transduced a majority of dopaminergic nigrostriatal neurons in the SNc and adjacent regions (data not shown).
Viral Expression
To assess rAAV >-synuclein expression levels for wt, S129A mutant, and S129D mutant, we performed Western blot analyses on striatal and midbrain extracts from 3 animals per group obtained at 6 weeks postinjection and compared these with extracts from the contralateral hemisphere injected with empty vector control. Blots from samples taken from wt, S129A, and S129D >-synuclein recipients probed with the LB509 synuclein antibody demonstrated strong human >-synuclein expression ipsilateral to the injection, as expected. We also probed blots with the Syn-1 antibody (BD Transduction, San Jose, CA), which recognizes both endogenous rat and human >-synuclein, to estimate the level of human >-synuclein overexpression for each rAAV compared with endogenous levels (Fig. 3) . Comparison of the >-synucleinY injected side with the contralateral striatum or midbrain, empty rAAV vector control, revealed levels of >-synuclein overexpression with a mean ratio (ipsilateral/contralateral side) of approximately twice that of endogenous rat >-synuclein.
Comparison of Nigrostriatal Toxicity
Unbiased stereological estimates of TH-positive cells in the SN were performed at 2 and 6 weeks postinjection of rAAV expressing wt or mutant, S129A or S129D, >-synuclein and compared with empty vector injections. In preliminary studies, subtle TH cell loss was observed at 2 weeks in both wt and mutant S129A and S129D groups (n = 2Y3 for each group). These findings were somewhat surprising given the early time point, but dopaminergic neurotoxicity for S129A has been observed as early as 4 weeks (28) . Qualitative comparison of TH cell loss with cresyl violetY stained sections confirmed proportional nigral cell loss and gliosis. Given the modest extent of cell loss at 2 weeks, we examined a larger cohort (6Y10 per group) at 6 weeks to further compare toxicity of wt and S129 mutant >-synucleins.
At 6 weeks postinjection, there was TH cell loss evident in the SNc for both wt and S129 mutant >-synuclein groups (Fig. 4) . Cell loss, as opposed to TH-phenotype loss, was confirmed by analysis of Nissl-stained sections and qualitative comparison with nigral TH cell loss. Stereological estimates of remaining TH cells in the SN demonstrated significant cell loss compared with empty vector control for wt (20.5% T 6.8%, p G 0.05), S129A (29.9% T 2.4%, p G 0.001), and S129D (27.0% T 6.7%, p G 0.01) mutants (F 3,24 = 9.96, p = 0.0002) (Fig. 5A) . The mean TH cell loss was 25.8% and ranged from 7% to 45% for all animals analyzed. Post hoc analysis revealed no significant differences in TH cell counts between wt, S129A, or S129D. Qualitative comparison of nigral TH staining at 6 weeks also did not differ.
Nigrostriatal TH and Dopamine Content
Immunostaining of striatal sections for TH did not show nigrostriatal terminal loss at 2 weeks. By contrast, at 6 weeks, TH immunostaining revealed loss of terminal density in the dorsal striatum for both S129A and S129D compared with wt recipients (Fig. 2) . Semiquantitative analysis, using scan array measurement of immunofluorescence optical density, also revealed small decreases relative to control in dorsal striatal TH-positive terminal density for wt and mutant FIGURE 5. Graphs of nigral tyrosine hydroxylase (TH) cell loss, striatal TH terminal density, and dopamine content. (A) Stereological estimates of TH cell loss in the substantia nigra at 6 weeks are expressed relative to empty vector control. Expression of both wild-type (wt) and S129 mutant >-synuclein resulted in significant TH cell loss (mean, 25.8%) compared with control (*p G 0.05, **p G 0.01, ***p G 0.001; F 3,24 = 9.96, p = 0.0002). However, TH cells did not differ among wt and S129A and S129D groups. (B) Optical density scan array analysis of striatal TH terminal density showed a 16% to 25% decrease for wt and S129 mutants, but no significant difference among groups (F 3,27 = 2.514, p = 0.080). (C) Relative striatal dopamine (DA) (compared with contralateral striatum injected with empty vector control) but not 3,4-dihydroxyphenlyacetic acid content was reduced in S129 mutants only. S129A and S129D recipients, but these findings did not achieve statistical significance (Fig. 5B) . Relative side-to-side comparisons of recipients with internal empty vector control showed a similar trend of decreased dorsal striatal THpositive terminal density for S129A and S129D mutant animals but also did not achieve significance.
To investigate potential changes in striatal dopaminergic innervation further, we also quantified striatal dopamine content at 6 weeks postinjection via high-performance liquid chromatography fractionation and electrochemical detection. Dopamine was extracted from striatal tissue ipsilateral to the SN injection of either wt or mutant (S129A or S129D) >-synuclein and compared with that extracted from the contralateral control striatum (SN injected with empty rAAV vector). In wt recipients, the striatal dopamine content and levels of its metabolite, 3,4-dihydroxyphenlyacetic acid, did not differ (Fig. 5C) . In contrast, relative dopamine content for S129A did significantly decrease, mean ratio (ipsilateral/ contralateral striatum) 0.66 T 0.04 (p = 0.006, 1 sample t-test for hypothesized ratio of 1). Dopamine levels also decreased for S129D (mean ratio, 0.59 T 0.15) but did not achieve statistical significance (p = 0.055). Similarly, striatal 3,4-dihydroxyphenlyacetic acid content for both S129A and S129D recipients demonstrated a trend toward decrease but were not significant. These results are consistent with the loss of 25% of TH-positive neurons in the SN.
Synuclein Toxicity, Cellular Aggregates, and Terminal Morphology
Examination of sections stained for human >-synuclein (LB509) at 2 and 6 weeks using bright-field and confocal microscopy revealed progressive changes in nigral cell morphology. Synuclein-positive cells in wt and mutant S129A and S129D cases were densely immunostained throughout the nucleus and cytoplasm (Fig. 6) . A subset of cells contained synuclein-positive aggregates at 6 weeks. Some larger cell aggregates costained for >-synuclein and ubiquitin. There were no qualitative differences in aggregate size or distribution between wt and S129A or S129A cases. Transduced cells frequently had dystrophic process as previously described (29) . Examination of nigrostriatal terminals immunostained for human >-synuclein also showed dystrophic changes and neurites, but no qualitative differences were noted between wt, S129A, and S129D animals.
DISCUSSION
We examined the role of >-synuclein phosphorylation at S129 by comparing the effects of overexpression of human wt and mutant >-synuclein S129A (alanine blocks phosphorylation) and S129D (mimics constitutive phosphorylation) in the rat nigrostriatal system. A targeted viral vectorYbased approach with rAAV2/8 was used to overexpress >-synuclein in the SNc. Neither S129 >-synuclein mutant seemed to significantly alter dopaminergic nigrostriatal toxicity in the rat PD model. At 2 weeks, early neurodegenerative changes and TH cell loss were apparent, and by 6 weeks, overexpression of wt and S129A and S129D mutants resulted in significant (20%Y30%) nigral dopaminergic cell loss (confirmed on Nissl-stained sections) compared with empty vector control. There were, however, no significant differences in dopaminergic nigrostriatal cell toxicity between wt, S129A, and S129D >-synuclein at 6 weeks. Furthermore, the size and distribution of >-synuclein aggregates did not differ among wt and either S129 mutant. Consistent with these findings, we did not detect major changes in striatal THterminal density or expression, although striatal dopamine content was decreased for S129A and S129D. The normal striatal dopamine levels for wt >-synuclein are not surprising FIGURE 6 . High-power photomicrographs of human >-synuclein (LB509) immunostaining of nigral neurons in wild-type (wt) (AYC), S129A (DYF), and S129D (G, H) recipients. Arrows indicate large intracytoplasmic >-synucleinYpositive aggregates. Most aggregates were either perinuclear or in the periphery (A and G). Panel (B) shows typical nuclear ghosting, consistent with neurodegenerative change. Dystrophic neurites in (C) have characteristic >-synucleinYpositive inclusions (arrowheads). Scale bar = 5 Km. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TH, tyrosine hydroxylase. because over 6 weeks, nongeriatric rodents have the ability to recover dopamine content after nigrostriatal lesion such as that caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (40) . The lack of recovery of dopamine content for both S129 mutants may thus suggest a decrease in functional neurochemical compensation or plasticity. Morphologically, >-synucleinYpositive nigrostriatal terminals in S129 recipients did not differ significantly from those of wt, but S129 mutants may alter dopamine release and synaptic function because these are putatively regulated by >-synuclein (41) .
These findings contrast with those from previous studies in similar Drosophila and rat PD models that also compared wt >-synuclein with S129A and S129D phosphorylation mutants (27, 28) . In the fly, S129D was more toxic to dopamine cells, and S129A was not only protective but also associated with an increase in >-synuclein aggregates. Recent data in rats found the opposite result and demonstrated increased toxicity for S129A and possible neuroprotective effects for S129D (28) . Toxicity was, however, similarly associated with a decrease in large insoluble >-synuclein aggregates, whereas neuroprotection correlated with the presence of cytoplasmic inclusions. By contrast, we observed no differences in toxicity or aggregate formation for wt >-synuclein or the phosphorylation mutants S129A and S129D in the rat.
Differences in study design may in part explain these differing results among studies. We used rAAV2/8 to deliver and overexpress >-synuclein in the rat SN, whereas Gorbatyuk et al (28) used a different serotype, rAAV2/5. Both of these rAAVs show enhanced transduction efficiency (i.e. increase in cell number and volume transduced) over that of rAAV2/2 in the rodent nigrostriatal system (33, 38, 42) . However, rAAV2/8 results in higher transgene expression than other rAAV serotypes, including rAAV2/2 and rAAV2/5 (37). One concern is that elevated levels of >-synuclein expression from high-titer AAV2/8 injections may mask differences in toxicity between wt and the S129 mutants. Therefore, we injected a moderate dose of each virus (1.4 Â 10 10 gc), resulting in only 20% to 30% nigral TH cell loss at 6 weeks. Using a similar dose of AAV2/5, Gorbatyuk et al (28) reported 40% to 60% cell loss for both wt and S129A, albeit at 8 weeks postinjection. Moreover, Western blot estimates of human >-synuclein expression compared with endogenous rat >-synuclein were also lower (only 2-fold) than that previously reported. These findings suggest that the amount of virus injected and, indirectly, the levels of >-synuclein expression in our study did not saturate the system. The fact that we saw toxicity in S129D recipients also argues that the viral dose was not too low because previously it seemed to be less toxic than the wt (28) .
Another difference between this and previous studies is the length of viral incubation. The time course for expression of the transgene is similar for both rAAV2/5 and rAAV2/8, although perhaps a bit more rapid for rAAV2/8 (38) . The 2-and 6-week time points for analysis we chose may have been too early to detect differences in toxicity among wt and S129 mutants. Even at 4 weeks, however, toxicity was noted for S129A by Gorbatyuk et al (28) and was evident by 2 weeks in this study. Moreover, by 6 weeks, the wt and both S129 mutant recipients showed significant dopaminergic cell toxicity.
Recent in vitro data on S129 phosphorylation and phosphomimics (e.g. S129D/E) may also help to explain differences in results from rat and fly PD models. Ser-129 phosphorylation increases >-synuclein conformational flexibility and seems to inhibit fibril formation. Although they are designed as phosphomimics, S129D/E does not exactly reproduce the effects of native phosphorylation (43) . Ser-129 phosphomimics only demonstrate local changes in conformational dynamics and form fibrils similar to those formed by wt in vitro but not as rapidly as S129A. Consistent with these findings, we found similar toxicity for wt and S129D >-synuclein. Rapid fibrillization caused by S129A presumably leads to increased >-synuclein aggregate formation that is thought to sequester toxic species. This hypothesis is supported by reduced S129A toxicity and increased >-synuclein inclusions seen in the fly (27) . Contradictory results for S129A are, however, seen in the rat (28) , possibly suggesting that whereas fibrils form, the S129A mutant in a mammalian system may also enhance formation of toxic >-synuclein oligomers. Together, these findings emphasize the importance of phosphorylation at S129 as a regulator of >-synuclein function but do not fully clarify its effects on toxicity.
Increasing evidence suggests that large >-synuclein aggregates may be neuroprotective and that S129 phosphorylation plays a role in aggregate formation (44) . A high proportion of >-synuclein in Lewy bodies is phosphorylated at S129 (24, 25) . Furthermore, coexpression of human >-synuclein and protein kinases, such as GRK5Vone of many kinases that phosphorylate at S129 (27, 45) Vis associated with >-synuclein aggregate formation in cell culture (46) . Recent data indicate, however, that S129 phosphorylation can also inhibit fibril formation and >-synuclein oligomerization, but with longer incubation times, fibrillary aggregates such as those found in Lewy bodies eventually form (43) . Lingering questions remain as to what influences >-synuclein phosphorylation, when it occurs (before, during, or after fibrillization and aggregate formation), and how it may mediate neurotoxicity.
Several kinases phosphorylate >-synuclein at S129, including casein kinases 1 and 2, and GRK2 and 5 (22, 45, 47) , but specific phosphatases have yet to be identified. Regulation of the >-synuclein phosphorylation state in vivo thus remains unclear, in particular, because of the multiple cellular compartments in which >-synuclein is found. Phosphorylation of >-synuclein by GRKs is enhanced by phospholipids (45) . Liposomal binding of >-synuclein and GRK seems to increase its kinase activity (48) . >-Synuclein phosphorylation by casein kinase 2 is similarly enhanced by liposomes. There is also evidence for Ca 2+ /calmodulin interaction with GPK5 and activation of >-synuclein phosphorylation (49) . Further study is necessary to identify other specific kinases and protein and membrane interactions involved in >-synuclein phosphorylation.
The function of >-synuclein remains largely unknown and further complicates our understanding of its role in PD pathophysiology. Putative functions include regulation of synaptic dopamine transport (41) , vesicle formation and trafficking (50) , mitochondrial function (41, 51) , and nuclear transcription (52) . How >-synuclein phosphorylation affects these functions is unclear, but disruption in any one of these could lead to dysfunction and potential neurotoxicity. Findings presented here suggest that the phosphorylation state at S129 and its effects in vivo are more complex than previously thought and that it may not play a critical role in mediating dopaminergic toxicity. A better understanding of >-synuclein phosphorylation and aggregate formation is clearly needed and will help target novel therapies.
